FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 37 filers reported holding FATE THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $12,000 | -14.3% | 4,596 | 0.0% | 0.00% | – |
| Q3 2016 | $14,000 | +100.0% | 4,596 | +6.2% | 0.00% | – |
| Q2 2016 | $7,000 | -12.5% | 4,327 | 0.0% | 0.00% | – |
| Q1 2016 | $8,000 | -46.7% | 4,327 | 0.0% | 0.00% | – |
| Q4 2015 | $15,000 | -34.8% | 4,327 | 0.0% | 0.00% | – |
| Q3 2015 | $23,000 | -11.5% | 4,327 | +5.9% | 0.00% | – |
| Q2 2015 | $26,000 | +136.4% | 4,085 | +87.5% | 0.00% | – |
| Q1 2015 | $11,000 | 0.0% | 2,179 | -3.1% | 0.00% | – |
| Q4 2014 | $11,000 | 0.0% | 2,248 | 0.0% | 0.00% | – |
| Q3 2014 | $11,000 | -15.4% | 2,248 | +8.4% | 0.00% | – |
| Q2 2014 | $13,000 | – | 2,073 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |